JPH0355447B2 - - Google Patents

Info

Publication number: JPH0355447B2
Authority: JP; Japan
Prior art keywords: cells; day; cell; culture; cancer
Prior art date: 1982-06-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP10851782A

Other languages

English (en)

Japanese (ja)

Other versions

JPS58225017A (ja

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-06-25

Filing date

1982-06-25

Publication date

1991-08-23

1982-06-25 Application filed filed Critical

1982-06-25 Priority to JP10851782A priority Critical patent/JPS58225017A/ja

1983-12-27 Publication of JPS58225017A publication Critical patent/JPS58225017A/ja

1991-08-23 Publication of JPH0355447B2 publication Critical patent/JPH0355447B2/ja

Status Granted legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 11
201000011510 cancer Diseases 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
239000000243 solution Substances 0.000 description 8
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
239000001569 carbon dioxide Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000036564 melanin content Effects 0.000 description 3
230000008099 melanin synthesis Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
239000008096 xylene Substances 0.000 description 3
PDEMCBLTVSFORZ-UHFFFAOYSA-N 5-chloro-3-phenyl-2,1-benzothiazole Chemical compound C=12C=C(Cl)C=CC2=NSC=1C1=CC=CC=C1 PDEMCBLTVSFORZ-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000001382 Experimental Melanoma Diseases 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
VLRWWADMWHAHFZ-UHFFFAOYSA-N 2-benzyl-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1CC1=CC=CC=C1 VLRWWADMWHAHFZ-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000004105 Penicillin G potassium Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108700002839 cactinomycin Proteins 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000012829 chemotherapy agent Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
235000019797 dipotassium phosphate Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
-1 folate antagonists Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
210000004013 groin Anatomy 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000019368 penicillin G potassium Nutrition 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
239000000649 purine antagonist Substances 0.000 description 1
239000003790 pyrimidine antagonist Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000003756 stirring Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Thiazole And Isothizaole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP10851782A 1982-06-25 1982-06-25 脱ガン剤 Granted JPS58225017A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP10851782A JPS58225017A (ja)	1982-06-25	1982-06-25	脱ガン剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10851782A JPS58225017A (ja)	1982-06-25	1982-06-25	脱ガン剤

Publications (2)

Publication Number	Publication Date
JPS58225017A JPS58225017A (ja)	1983-12-27
JPH0355447B2 true JPH0355447B2 (fr)	1991-08-23

Family

ID=14486795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10851782A Granted JPS58225017A (ja)	1982-06-25	1982-06-25	脱ガン剤

Country Status (1)

Country	Link
JP (1)	JPS58225017A (fr)

1982
- 1982-06-25 JP JP10851782A patent/JPS58225017A/ja active Granted

Also Published As

Publication number	Publication date
JPS58225017A (ja)	1983-12-27

Publication	Publication Date	Title
Braughler et al.	1988	A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells.
HU229864B1 (en)	2014-10-28	Use of amide compounds for the preparation of medicaments
JP2001516694A (ja)	2001-10-02	プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
JP2572558B2 (ja)	1997-01-16	ポドフイロトキシンよりなるマラリヤの治療剤
JP2003514850A (ja)	2003-04-22	薬剤を調製するためのインジルビン誘導体の使用
SU927111A3 (ru)	1982-05-07	Способ получени оксимэфиров или их солей
JPH0355447B2 (fr)	1991-08-23
WO1997002822A1 (fr)	1997-01-30	Medicament destine a soigner les affections du cerveau
FI85142C (fi)	1992-03-10	Foerfarande foer framstaellning av ergolinestrar.
JPH0314807B2 (fr)	1991-02-27
CN101519385B (zh)	2011-04-13	具有促进干细胞增殖作用的小分子化合物及其用途
JPH07258132A (ja)	1995-10-09	新規ヒドロキノン化合物
JPS6366288B2 (fr)	1988-12-20
US20030225148A1 (en)	2003-12-04	Biological methods of use of 4-amino-3-mercapto-triazoles
CZ380596A3 (en)	1997-08-13	Salts of 2-(2,6-dichlorophenyl)amino)phenylacetoxyacetic acid with cations of organic bases, process of their preparation, pharmaceutical compositions containing thereof and their use
US4086352A (en)	1978-04-25	Certain 6-aryloxy-2-oxo-1-aza-4-thia-spiro[4,5]decanes
CA2346506C (fr)	2009-01-13	Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1
JPH045240A (ja)	1992-01-09	抗痴呆剤
JPH06345644A (ja)	1994-12-20	自己免疫性疾患治療剤
HK40112808A (zh)	2025-01-28	用於治疗与核糖体障碍相关的贫血的组合物和方法
HK40105830A (zh)	2024-08-23	用於治疗与核糖体障碍相关的贫血的组合物和方法
JP2004518716A (ja)	2004-06-24	骨多孔症予防および治療用医薬組成物
NZ199917A (en)	1985-07-31	1,3,4-thiadiazoles
WO2021123928A1 (fr)	2021-06-24	Analogues deutérés de sélénophénochromènes, leur synthèse, et procédés d'utilisation desdits agents
HK40105387A (zh)	2024-08-09	用於治疗红细胞增多症的组合物和方法